240 related articles for article (PubMed ID: 12703204)
1. Farnesyltransferase inhibitors.
Adjei AA
Cancer Chemother Biol Response Modif; 2002; 20():151-67. PubMed ID: 12703204
[No Abstract] [Full Text] [Related]
2. Farnesyltransferase inhibitors.
Adjei AA
Cancer Chemother Biol Response Modif; 2001; 19():149-64. PubMed ID: 11686012
[No Abstract] [Full Text] [Related]
3. Farnesyltransferase inhibitors as anticancer agents: current status.
Zhu K; Hamilton AD; Sebti SM
Curr Opin Investig Drugs; 2003 Dec; 4(12):1428-35. PubMed ID: 14763128
[TBL] [Abstract][Full Text] [Related]
4. Inhibitors of farnesyltransferase: a rational approach to cancer chemotherapy?
Bell IM
J Med Chem; 2004 Apr; 47(8):1869-78. PubMed ID: 15055985
[No Abstract] [Full Text] [Related]
5. Farnesyltransferase inhibitors: an overview of the results of preclinical and clinical investigations.
Brunner TB; Hahn SM; Gupta AK; Muschel RJ; McKenna WG; Bernhard EJ
Cancer Res; 2003 Sep; 63(18):5656-68. PubMed ID: 14522880
[TBL] [Abstract][Full Text] [Related]
6. Immunohistochemical assays of farnesyltransferase inhibition in patient samples.
Adjei AA
Methods Mol Med; 2003; 85():141-5. PubMed ID: 12710205
[No Abstract] [Full Text] [Related]
7. Effects of statins and farnesyltransferase inhibitors on the development and progression of cancer.
Graaf MR; Richel DJ; van Noorden CJ; Guchelaar HJ
Cancer Treat Rev; 2004 Nov; 30(7):609-41. PubMed ID: 15531395
[TBL] [Abstract][Full Text] [Related]
8. Opinion: Searching for the elusive targets of farnesyltransferase inhibitors.
Sebti SM; Der CJ
Nat Rev Cancer; 2003 Dec; 3(12):945-51. PubMed ID: 14737124
[No Abstract] [Full Text] [Related]
9. The development of protein farnesyltransferase inhibitors as signaling-based anticancer agents.
Ohkanda J; Blaskovich MA; Sebti SM; Hamilton AD
Prog Cell Cycle Res; 2003; 5():211-7. PubMed ID: 14593715
[TBL] [Abstract][Full Text] [Related]
10. [Inhibitors of farnesyltransferase: a new approach for development of potential cancer drugs].
Schlitzer M
Pharm Unserer Zeit; 1998 Nov; 27(6):278-88. PubMed ID: 9894422
[No Abstract] [Full Text] [Related]
11. Farnesyltransferase inhibitors: antineoplastic properties, mechanisms of action, and clinical prospects.
Prendergast GC; Oliff A
Semin Cancer Biol; 2000 Dec; 10(6):443-52. PubMed ID: 11170866
[TBL] [Abstract][Full Text] [Related]
12. Non-thiol farnesyltransferase inhibitors: N-(4-tolylacetylamino-3-benzoylphenyl)-3-arylfurylacrylic acid amides.
Mitsch A; Wissner P; Silber K; Haebel P; Sattler I; Klebe G; Schlitzer M
Bioorg Med Chem; 2004 Sep; 12(17):4585-600. PubMed ID: 15358286
[TBL] [Abstract][Full Text] [Related]
13. Non-thiol farnesyltransferase inhibitors: FTase-inhibition and cellular activity of benzophenone-based bisubstrate analogue farnesyltransferase inhibitors.
Mitsch A; Bergemann S; Gust R; Sattler I; Schlitzer M
Arch Pharm (Weinheim); 2003 Jul; 336(4-5):242-50. PubMed ID: 12916059
[TBL] [Abstract][Full Text] [Related]
14. Design, synthesis, and structure-activity relationships of tetrahydroquinoline-based farnesyltransferase inhibitors.
Lombardo LJ; Camuso A; Clark J; Fager K; Gullo-Brown J; Hunt JT; Inigo I; Kan D; Koplowitz B; Lee F; McGlinchey K; Qian L; Ricca C; Rovnyak G; Traeger S; Tokarski J; Williams DK; Wu LI; Zhao Y; Manne V; Bhide RS
Bioorg Med Chem Lett; 2005 Apr; 15(7):1895-9. PubMed ID: 15780629
[TBL] [Abstract][Full Text] [Related]
15. A new class of highly potent farnesyl diphosphate-competitive inhibitors of farnesyltransferase.
Aoyama T; Satoh T; Yonemoto M; Shibata J; Nonoshita K; Arai S; Kawakami K; Iwasawa Y; Sano H; Tanaka K; Monden Y; Kodera T; Arakawa H; Suzuki-Takahashi I; Kamei T; Tomimoto K
J Med Chem; 1998 Jan; 41(2):143-7. PubMed ID: 9457237
[No Abstract] [Full Text] [Related]
16. [Developments in chemotherapy; cytostatic agents with an increased specificity and other forms of administering cytotoxic antineoplastic agents].
Eskens FA; de Jonge MJ; Verweij J
Ned Tijdschr Geneeskd; 2001 Nov; 145(46):2208-13. PubMed ID: 11757242
[TBL] [Abstract][Full Text] [Related]
17. The farnesyltransferase inhibitor L744,832 reduces hypoxia in tumors expressing activated H-ras.
Cohen-Jonathan E; Evans SM; Koch CJ; Muschel RJ; McKenna WG; Wu J; Bernhard EJ
Cancer Res; 2001 Mar; 61(5):2289-93. PubMed ID: 11280800
[TBL] [Abstract][Full Text] [Related]
18. Farnesyl transferase inhibitors: mechanism of action, translational studies and clinical evaluation.
Bishop WR; Kirschmeier P; Baum C
Cancer Biol Ther; 2003; 2(4 Suppl 1):S96-104. PubMed ID: 14508086
[No Abstract] [Full Text] [Related]
19. Farnesyltransferase inhibitors.
Adjei AA
Cancer Chemother Biol Response Modif; 2003; 21():127-44. PubMed ID: 15338743
[No Abstract] [Full Text] [Related]
20. Farnesyltransferase inhibitors (FTIs) in myeloid malignancies.
Karp JE; Lancet JE
Ann Hematol; 2004; 83 Suppl 1():S87-8. PubMed ID: 15124688
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
